Jennison Associates LLC is a privately owned investment management firm based in New York City, founded in 1969. It primarily serves a diverse range of clients, including individuals, high-net-worth individuals, pension plans, corporations, and various organizations, providing tailored investment solutions. The firm manages over $93 billion in assets through separately managed accounts and commingled vehicles, including mutual funds and hedge funds. Jennison Associates specializes in equity, fixed income, and balanced portfolios, investing globally across public markets and alternative investments. Their investment strategy encompasses growth and value stocks, with a focus on multi-cap companies, and includes investments in dividend-paying stocks and master limited partnerships. For fixed income investments, the firm targets investment-grade securities from a wide array of issuers, including U.S. government and corporate entities. With a commitment to rigorous analysis, Jennison employs both fundamental and quantitative approaches to stock selection, supported by in-house and external research. The firm operates as a subsidiary of PGIM, Inc., and has additional offices in Waltham, Massachusetts.
Managing Director and Co-Head of Large Cap Growth Equity
Erik Brown
Managing Director
Benjamin F. Bryan
Managing Director and Equity Research Analyst
Peter Clark
Managing Director and Head of Client Portfolio Management, Product and Strategy
Brannon Cook
Managing Director, Global Infrastructure Portfolio Manager and Research Analyst
Thomas Davis
Managing Director and Portfolio Manager
Ubong Edemeka
Managing Director and Portfolio Manager
James Gaul
Managing Director, Head of Fixed Income and Portfolio Manager, Fixed Income Credit
Zachary Gill
Principal, Equity Research Analyst
Shaun Hong
Managing Director
Owen Hyde
Managing Director and Equity Research Analyst
Rebecca Irwin
Managing Director and Portfolio Manager, Global Equity and Global Sustainable Strategies and Research Analyst, consumer discretionary and consumer staples
Erika Klauer
Managing Director, Technology Equity Portfolio Manager and Research Analyst
Owuraka Koney
Managing Director and Equity Research Analyst
Natasha Kuhlkin
Managing Director and Large Cap Growth Equity Portfolio Manager
Albert Kwok
Managing Director, Emerging Markets Equity Portfolio Manager and Research Analyst
Kathleen Ann McCarragher
Managing Director
Lori McEvoy
Managing Director and Global Head of Distribution
Jason Minkler
Managing Director
Sara Moreno
Managing Director and Emerging Markets Equity Portfolio Manager and Research Analyst
Jeffrey Nathan
Managing Director and Global Equity Research Analyst
Debra Netschert
Managing Director and Portfolio Manager, Healthcare Strategies
Steven Postal
Managing Director and Equity Research Analyst
Dmitri Rabin
Managing Director and Fixed Income Rates and Structured Portfolio Manager
David Ravera
Managing Director and Equity Research Analyst
Douglas Richardson
Managing Director and Client Portfolio Manager Global, International, Emerging Markets and Large Cap, Growth Equity Strategies
Nick Rubinstein
Managing Director, Technology Equity Portfolio Manager and Research Analyst
Eric Sartorius
Managing Director, Portfolio Manager for Small Cap Core and Mid Cap Growth Strategies and Research Analyst, Information Technology
Spiros Segalas
Founder, President and Chief Investment Officer
Raj Shant
Managing Director and Client Portfolio Manager
Meagan Speight
Managing Director and Equity Research Analyst
Eric Staudt
Managing Director and Fixed Income Credit Portfolio Manager
Kelly Thomas
Managing Director and Equity Research Analyst
Andrew M. Tucker
Managing Director
Janice Vrdoljak
Managing Director
Charlotte Walsh
Managing Director
Stephen Weiss
Managing Director
Thomas Wolfe
Managing Director
Miriam Zussman
Managing Director and Fixed Income Credit Portfolio Manager
27 past transactions
Electric Last Mile Solutions
Post in 2021
Electric Last Mile, Inc. designs and manufactures electric vehicles specifically for last mile delivery, aiming to enhance efficiency and profitability for businesses. Incorporated in 2020 and headquartered in Auburn Hills, Michigan, the company is pioneering a new era of clean, connected commercial vehicles. Its flagship product, the Urban Delivery, is expected to be the first Class 1 commercial electric vehicle available in the U.S. market, reflecting the company's commitment to innovative and sustainable transportation solutions.
Talkspace
Post in 2021
Talkspace is a behavioral healthcare company that provides online therapy services through its technology platform, connecting users with licensed therapists, psychologists, and psychiatrists. The platform allows for confidential communication and unlimited messaging therapy, enabling individuals to seek help for various mental health conditions without the need for in-person appointments. This approach caters to those who may find it difficult to open up in traditional therapy settings or who face financial barriers to accessing care. Talkspace serves a diverse clientele, including health plans, enterprises, and individual subscribers, generating revenue primarily from payor and direct-to-enterprise clients. The company focuses on delivering quality mental health support, aiming to improve the well-being of its users globally.
Field Trip Health
Post in 2021
Field Trip Health is providing simple, evidence-based therapies for healing and heightening engagement with the world. It was established in 2019 and is based in Toronto, Canada.
Clover Health
Venture Round in 2020
Clover Health Inc. is a health insurance company that specializes in providing Medicare Advantage plans primarily for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company operates in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health utilizes a Preferred Provider Organization (PPO) platform to enhance the quality of life for its members and their healthcare providers. The company employs patient-centered analytics and a dedicated care management team to identify potential health risks and deliver preventive care, thereby aiming to minimize avoidable spending and manage chronic diseases. Its proprietary software platform, Clover Assistant, offers personalized insights to physicians, supporting early detection and effective management of chronic conditions. Clover Health generates the majority of its revenue from its insurance segment, which includes both PPO and HMO plans.
Allogene Therapeutics
Convertible Note in 2018
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing off-the-shelf, genetically engineered allogeneic T cell therapies for cancer treatment. The company's pipeline includes UCART19, in development for relapsed/refractory acute lymphoblastic leukemia, and several preclinical allogeneic CAR T therapies targeting various cancers. Allogene's approach uses gene editing and advanced manufacturing technologies to create a scalable, broader patient eligibility option compared to autologous therapies. Revenue is primarily generated through collaborations and licensing agreements.
Syndax Pharmaceuticals
Series C in 2015
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing therapies for cancer treatment. The company's lead product, entinostat, is a class I HDAC inhibitor currently in Phase III clinical trials for advanced hormone receptor positive, HER2 negative breast cancer. Additionally, entinostat is being tested in combination with Keytruda and Tecentriq in Phase Ib/II trials for non-small cell lung cancer and metastatic breast cancer. Another significant candidate, SNDX-5613, is a selective inhibitor targeting the Menin-MLL interaction, undergoing Phase I/II trials for acute leukemias. The company is also developing SNDX-6352, a monoclonal antibody for chronic graft versus host disease, currently in Phase I/II trials. Syndax has established collaborations with major pharmaceutical companies and research organizations, enhancing its research and development capabilities. Founded in 2005, Syndax Pharmaceuticals aims to address critical needs in oncology through innovative therapeutic approaches.
WaVe Life Sciences
Series B in 2015
Wave Life Sciences Ltd. is a clinical-stage genetic medicine company focused on developing innovative RNA-based therapies. Utilizing its proprietary PRISM platform, the company designs, optimizes, and produces stereopure oligonucleotides aimed at addressing genetic defects. By targeting ribonucleic acid (RNA), Wave aims to either diminish the production of harmful proteins or convert dysfunctional proteins into functional ones. The company's primary focus is on neurology, particularly disorders affecting the central and neuromuscular systems. Wave Life Sciences has established research and collaboration agreements with major pharmaceutical companies, including Pfizer and Takeda, to further advance its therapeutic programs. Founded in 2012 and headquartered in Singapore, Wave Life Sciences is dedicated to delivering transformative treatments for patients with genetically defined diseases.
Ovid Therapeutics
Series B in 2015
Ovid Therapeutics Inc. is a biopharmaceutical company based in New York, focused on developing innovative therapies for patients with neurological disorders, particularly rare diseases. Founded in 2014, the company is advancing a promising pipeline of drug candidates aimed at treating conditions such as angelman syndrome and fragile X syndrome. Its lead candidate, OV101, is in Phase III clinical trials for angelman syndrome and has completed Phase II trials for fragile X syndrome. Additionally, Ovid is developing OV935, currently in Phase II trials for cyclin-dependent kinase-like 5 deficiency disorder and Dravet syndrome. The company is also researching OV329 for infantile spasms and OV881 as a microRNA gene therapy for angelman syndrome. Ovid Therapeutics has established collaborations and licensing agreements with various pharmaceutical and research organizations to enhance its development efforts. The company's commitment to addressing unmet medical needs is underpinned by strong intellectual property and a focus on safe, effective treatments for patients facing challenging neurological conditions.
Editas Medicine
Series B in 2015
Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.
GenSight Biologics
Series B in 2015
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.
Afferent Pharmaceuticals
Series C in 2015
Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, founded in 2009. The company focuses on developing small molecule drugs aimed at treating chronic pain and various neurogenic disorders by targeting P2X3 receptors in nerve fibers. Its lead compound, AF-219, has completed two Phase 1 clinical studies and is designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy, as well as respiratory and urological issues.
Cogent Biosciences
Series B in 2015
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.
Regenxbio
Series D in 2015
Regenxbio Inc. is a clinical-stage biotechnology company focused on developing gene therapy products to address genetic disorders and enable cells to produce therapeutic proteins and antibodies. The company leverages its proprietary NAV Technology Platform, which utilizes adeno-associated virus vectors for gene delivery. Regenxbio's lead product candidate, RGX-314, is under investigation in a Phase I/IIa clinical trial for wet age-related macular degeneration. Other notable product candidates include RGX-121 and RGX-111, which are in clinical trials for mucopolysaccharidosis type II and I, respectively, as well as RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Additionally, Regenxbio licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and collaborates with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.
Dimension Therapeutics
Series B in 2015
Dimension Therapeutics, Inc. is a gene therapy company dedicated to developing innovative treatments for rare and metabolic diseases linked to liver function. Founded in 2013 and based in Cambridge, Massachusetts, the company has established a robust pipeline of gene therapy candidates. Its lead products include DTX101 for hemophilia B and DTX201 for hemophilia A, alongside other programs targeting conditions such as ornithine transcarbamylase deficiency, glycogen storage disease type Ia, phenylketonuria, Wilson disease, and citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, leveraging its extensive patent portfolio related to NAV vector technology. This partnership enhances Dimension's ability to advance its gene therapy initiatives, particularly in the realm of adeno-associated virus therapeutics. In 2017, Dimension Therapeutics became a subsidiary of Ultragenyx Pharmaceutical Inc.
Natera
Series F in 2015
Natera, Inc. is a diagnostic and research company specializing in genetic testing services, particularly in the areas of preconception and prenatal diagnostics. Founded in 2003 and headquartered in San Carlos, California, Natera offers a range of products including the Panorama non-invasive prenatal test, which screens for chromosomal abnormalities in fetuses, and Vistara, a test for single-gene mutations. Additionally, the company provides Horizon carrier screening to assess carrier status for various genetic diseases, and Spectrum, which analyzes genetic conditions during in vitro fertilization. Natera's Anora product analyzes fetal chromosomes to understand miscarriage causes, while its non-invasive paternity tests determine parentage through fetal DNA analysis. The company's Signatera technology focuses on circulating tumor DNA to monitor cancer recurrence. Natera distributes its products through a direct sales force and a network of approximately 100 laboratory and distribution partners, both domestically and internationally. The company collaborates with BGI Genomics to develop genetic testing assays and has partnered with Foundation Medicine for personalized cancer monitoring assays.
Aeglea BioTherapeutics
Series B in 2015
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company based in Austin, Texas, specializing in the development of human enzyme therapeutics for rare genetic and cancer-related diseases. Founded in 2013, the company is focused on addressing unmet medical needs through innovative enzyme therapies. Its lead product candidate, pegzilarginase, is a recombinant human Arginase 1 enzyme currently undergoing a Phase III trial to assess its safety and efficacy in treating Arginase 1 deficiency. Additionally, Aeglea has a preclinical pipeline that includes several candidates targeting various metabolic disorders, such as ACN00177 for homocystinuria, AEB5100 for the degradation of plasma cystine and cysteine, and AEB2109, which focuses on methionine degradation. Aeglea BioTherapeutics aims to make significant advancements in the treatment of rare metabolic diseases through its specialized enzyme therapies.
Aduro BioTech
Series D in 2015
Aduro Biotech is a clinical-stage biopharmaceutical company headquartered in Berkeley, California, established in 2000. The company specializes in the discovery, development, and commercialization of therapies that leverage the body's immune system to treat challenging diseases. Aduro is advancing several product candidates, including ADU-S100, which is undergoing various clinical trials for applications in treating advanced solid tumors, melanoma, and squamous cell carcinoma of the head and neck. Additionally, Aduro is developing BION-1301, a monoclonal antibody for IgA nephropathy, and exploring CD27, a co-stimulatory receptor, in preclinical studies. The company has formed collaboration agreements with major pharmaceutical firms such as Novartis, Eli Lilly, and Merck, alongside license agreements with research institutions like UC Berkeley and Memorial Sloan Kettering Cancer Center.
Nivalis Therapeutics
Venture Round in 2014
Nivalis Therapeutics is focused on developing innovative therapies aimed at treating cystic fibrosis (CF) by preserving intracellular S-nitrosoglutathione (GSNO), a molecule involved in cell signaling and implicated in the disease's pathophysiology. The company's lead candidate, N91115, specifically targets patients with the F508del mutation, the most prevalent mutation associated with CF. Founded in 2007 and headquartered in Boulder, Colorado, Nivalis Therapeutics is committed to improving the lives of individuals affected by cystic fibrosis and supporting their families through its research and development efforts.
Flex Pharma
Venture Round in 2014
Flex Pharma, Inc. is a biotechnology company focused on developing and commercializing treatments for muscle cramps, spasms, and spasticity linked to neurological conditions and exercise. The company operates in two segments: Consumer Operations and Drug Development. Its lead drug candidate, FLX-787, is a dual transient receptor potential V1/A1 ion channel activator, which has completed an exploratory Phase II clinical trial in Australia targeting multiple sclerosis patients. Additionally, Flex Pharma offers HOTSHOT, a consumer beverage designed to prevent and treat exercise-associated muscle cramps. The company markets HOTSHOT products online through its direct-to-consumer website and third-party platforms that provide international shipping. Founded in 2014 and based in Boston, Massachusetts, Flex Pharma was acquired by Salarius Pharmaceuticals in 2019.
Bellicum Pharmaceuticals
Series C in 2014
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing innovative cellular immunotherapies for the treatment of hematological cancers and solid tumors. The company is advancing its product candidates, including BPX-601, an autologous GoCAR-T therapy aimed at solid tumors expressing prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy targeting solid tumors that express human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control of immune system components to enhance therapeutic efficacy. The company collaborates with various institutions, including Adaptimmune Therapeutics and Baylor College of Medicine, to further its research and development efforts. Founded in 2004, Bellicum Pharmaceuticals continues to make strides in cancer treatment through its novel immunotherapeutic approaches.
Otonomy
Series D in 2014
Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing therapeutics for ear disorders. The company markets OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for Ménière’s disease; OTO-313, a formulation for tinnitus in Phase I/II trials; and OTO-413, aimed at repairing cochlear synaptopathy and addressing speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, designed to prevent cisplatin-induced hearing loss, and OTO-6XX, which focuses on hair cell regeneration for severe hearing loss. Otonomy employs a proprietary formulation platform that enables sustained drug delivery from a single administration, enhancing treatment options for various ear-related conditions. The company also has strategic collaborations for gene therapy aimed at congenital hearing loss. Founded in 2008, Otonomy continues to lead advancements in otology through innovation and research.
PTC Therapeutics
Private Equity Round in 2013
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.
Puma Biotechnology
Private Equity Round in 2011
Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. The company focuses on acquiring and advancing drug candidates that have completed initial clinical testing. Its primary product, NERLYNX, is an oral formulation of neratinib, which is used for treating HER2-positive breast cancer. In addition to neratinib, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets epidermal growth factor receptors HER1, HER2, and HER4. The company has established a licensing agreement with Pfizer for the development and commercialization of these drug candidates. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology is committed to enhancing treatment outcomes for patients with various forms of cancer.
Merrimack Pharmaceuticals
Private Equity Round in 2011
Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on discovering, designing, and developing innovative therapies for the treatment of cancer and autoimmune diseases. Merrimack employs a systems biology approach, utilizing multidisciplinary capabilities to create functional and predictive computational models of biological systems, particularly cell signaling networks. In addition to its internal development efforts, the company collaborates with third parties to further process and commercialize its products, enhancing its ability to bring novel therapeutics and diagnostics to market.
Chemocentryx
Series C in 2006
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focused on developing and commercializing innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company's lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently undergoing Phase III trials for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and a Phase IIb trial for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing other drug candidates, including CCX140, an inhibitor targeting the CCR2 chemokine receptor, which has completed Phase II trials for diabetic nephropathy and is being developed for focal segmental glomerulosclerosis; CCX507, a second-generation CCR9 inhibitor that has completed Phase I trials; and CCX872, a selective CCR2 inhibitor currently in Phase Ib trials for stage 3 and 4 pancreatic cancer. ChemoCentryx aims to address the underlying immune system dysfunction associated with various conditions through its targeted therapeutics.
Merrimack Pharmaceuticals
Series E in 2006
Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on discovering, designing, and developing innovative therapies for the treatment of cancer and autoimmune diseases. Merrimack employs a systems biology approach, utilizing multidisciplinary capabilities to create functional and predictive computational models of biological systems, particularly cell signaling networks. In addition to its internal development efforts, the company collaborates with third parties to further process and commercialize its products, enhancing its ability to bring novel therapeutics and diagnostics to market.
Avanir Pharmaceuticals
Post in 2005
Avanir Pharmaceuticals is a biopharmaceutical company based in Aliso Viejo, California, dedicated to the research, development, and commercialization of innovative medicines for central nervous system disorders with significant unmet medical needs. The company focuses on creating novel pharmaceutical products to treat conditions such as acute migraine, Alzheimer's disease, schizophrenia, dementia, and behavioral dysfunction. Through extensive investment in its pipeline, Avanir aims to improve the quality of life for patients and their families affected by these serious chronic diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.